Sector portfolio · Corporate investor · Switzerland
Novartis Venture Fund's Biotech portfolio
Novartis Venture Fund has backed 39 Biotech startups in rounds we track, $3.3B between them, shown by the stage each has reached. The best-funded is Novimmune.
39startups backed
4stages
$3.3Braised between them
Series Bbiggest stage
Series B
15
Series A
10
Funding by segment
- Series B$1.8B15
- Series A$449M10
- Series C and later$761M10
- Stage not reported$333M4
Where they are based
- United States22$2.0B
- United Kingdom8$591M
- Switzerland4$493M
- France2$175M
- Finland1$20M
- Canada1$20M
United States
United Kingdom
Switzerland
France
Finland
CanadaFounded
23Earlier
212
213
14
115
216
17
118
119
20
121
122
123
24
25
26
4 without a founding year on record.
Total raised
- Under $1M0
- $1M to $10M1
- $10M to $50M14
- $50M to $250M22
- $250M to $1B2
- $1B and over0
Each dot is a startup: the year it was founded across, the total it has raised up (each line is ten times the one below). Pick a segment to pick it out.
35 of 39 startups shown; the rest have no founding year or amount on record.
- 1 to 2
- 3 to 7
- 8 to 24
- 25 to 99
- 100 and more
- United States22
- United Kingdom8
- Switzerland4
- France2
- Finland1
- Canada1
Startups by country, 6 countries in all.
Segment by segment
Series B
15 startups · $1.8B raised
NovImmuneNovImmmune develops therapeutic monoclonal antibodies to treat patients suffering from immune-related disorders.Switzerland$352M
Aeglea BioTherapeuticsAeglea BioTherapeutics is a clinical-stage biotechnology company that develops enzyme therapies for rare metabolic diseases.United States$266M
Galera TherapeuticsGalera Therapeutics develops therapeutic agents for preventing damage to normal tissues during the radiation treatment of cancer.United States$219M- CTCapstan TherapeuticsCapstan Therapeutics is advancing cell engineering to develop therapeutics for a broad range of diseases.United States$175M
Sidewinder TherapeuticsSidewinder Therapeutics is a biotechnology company that offers life-saving therapies for cancer and rare diseases.United States$137M
Bicycle TherapeuticsBicycle Therapeutics is developing a technology for the creation of new generation biotherapeutics.United Kingdom$110M
EpiBiologicsEpiBiologics is a biotechnology company based in San Mateo, California, founded in 2022.United States$107M
GenSight BiologicsGenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases.France$80M
Series A
10 startups · $449M raised
AstronauTxAstronauTx Ltd.United Kingdom$124M
Vivet TherapeuticsVivet Therapeutics is a biotechnology company developing gene therapy treatments for orphan diseases.France$96M- EExpansionUnited States$55M
RenovacorNo mercado desde 2009, a Renovacor Tintas se diferencia pela fabricação de tintas e revestimentos acrílicos de qualidade que contaUnited States$41M- IImmunitasUnited States$39M
Quartet MedicineQuartet Medicine is a private, biotechnology company focused on discovering and developing novel treatments for chronic pain and iUnited Kingdom$23M
Immune Targeting SystemsImmune Targeting Systems develops synthetic vaccines for mutating viruses, improving the quality of life for those infected by viruses.United Kingdom$20M
Forendo PharmaForendo Pharma is a developer of novel drugs intended for the treatment of urological and other endocrinological diseases.Finland$20M
Series C and later
10 startups · $761M raised
FORMA TherapeuticsFORMA Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of transformative medicines.United States$143M- FF2GUnited Kingdom$136M
- AGAtlas GeneticsUnited Kingdom$111M
FORE BiotherapeuticsFore Biotherapeutics is a clinical-stage precision oncology company based in Philadelphia, PA.United States$108M
Effector TherapeuticsEffector Therapeutics is an early-stage company focused on the discovery and development of small molecule cancer therapeutics.United States$99M- SSSeventh Sense BiosystemsUnited States$52M
- RMROX MedicalUnited States$50M
- TTTorreyPines TherapeuticsTorreyPines Therapeutics engages in the discovery and development of small molecule compounds in the United States.-$35M
Stage not reported
4 startups · $333M raised
CelladonCelladon is a biotechnology company developing molecular therapies for the treatment of heart failure.United States$172M- AAnokionSwitzerland$75M
- LPLigoCyte PharmaceuticalsLigoCyte Pharmaceuticals is focused on developing vaccines and monoclonal antibodies for gastrointestinal and respiratory indications.United States$72M
- NPNeuroGenetic PharmaceuticalsNeurogenetic Pharmaceuticals is engaged in the R&D of therapeutics for neurodegenerative disorders such as Alzheimer’s disease.United States$14M
How this map is made. Every startup here works in Biotech and has raised money in a round we track that names Novartis Venture Fund as an investor. Each sits under the stage of its latest round. Rebuilt nightly; updated 15 November 2026.
More portfolio maps
All portfoliosCo-investorsWho invests with Novartis Venture Fund52 co-investorsInvestments abroadNovartis Venture Fund's investments in the United States27 startups · $2.2BSector portfolioM Ventures' AI portfolio28 startups · $593MSector portfolioRoche Venture Fund's Biotech portfolio11 startups · $1.2BSector portfolioY Combinator's AI portfolio1,143 startups · $44BSector portfolioY Combinator's Fintech portfolio338 startups · $24B
Raising from investors like Novartis Venture Fund?
Find the investors who back startups like yours, with their cheques, rounds and partners, in the app with filters, lists and exports.